Phase I ATLCAR.CD30.CCR4: CAR‑T cells targeting CD30 with CCR4‑mediated tumor homing

This study evaluates ATLCAR.CD30.CCR4 therapy—administered alone or with ATLCAR.CD30 cells—to determine safe dosing in patients with relapsed/refractory CD30+ lymphomas (including Hodgkin, Grey Zone, and T‑cell variants). Conducted by UNC Lineberger Comprehensive Cancer Center, it is the first trial to combine these modified CAR‑T cells for improved tumor homing.